Director of Innovation NABP Mount Prospect, IL, United States
Disclosure(s):
Libby Baney, JD: No financial relationships to disclose
Justin Macy, PharmD, JD: No financial relationships to disclose
Abstract: Do you believe the U.S. drug supply chain is closed and safe? We did too, but this presentation will present the dark underside – exposing how legal loopholes, lack of enforcement, and assumption of risk create vulnerabilities. We will share new just-released data from the ASOP Global Foundation on consumers’ beliefs and behavior when buying medicine. We will discuss threats to employees from third-party “discount” vendors and developments impacting patient access to controlled substances. Additionally, as demand for GLP-1 drugs has surged so have drug importation and counterfeit risks. We’ll share recent cases and Congressional developments. On a more positive note, we’ll show the real-world impact NABP’s PULSE has on identifying suspect drug product in the supply chain.
Learning Objectives:
Get new insights and data from ASOP Global Foundation’s Consumer Survey 2025
Observe real world instances where NABP’s PULSE was used to identify suspect or illegitimate drug product.
Understand decisions from the ITC and related cases concerning drug importation.
Learn about Congressional and FDA developments impacting counterfeiting, illegal compounding, and importation.
